The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
Abstract
The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (n=22 277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (n=1090) or overall survival (n=1287). A Kaplan–Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot.com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; P=3.7×10−5, hazard ratio (HR)=1.4), CDKN1B (P=5.4×10−5, HR=1.4), KLK6 (P=0.002, HR=0.79), IFNG (P=0.004, HR=0.81), P16 (P=0.02, HR=0.66), and BIRC5 (P=0.00017, HR=0.75) were associated with survival. The combination of several probe sets can further increase prediction efficiency. In summary, we developed a global online biomarker validation platform that mines all available microarray data to assess the prognostic power of 22 277 genes in 1287 ovarian cancer patients. We specifically used this tool to evaluate the effect of 37 previously published biomarkers on ovarian cancer prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Self-citationInternational Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., Gajewski, W., Kurman, R., Bast, R. C., & Skates, S. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.031 · Cited by 875
Evaluation of gene expression measurements from commercial microarray platforms
Tan, P. K. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg763 · Cited by 706
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Cited by
Lánczky, A., & Győrffy, B. (2021) · Journal of Medical Internet Research · doi:10.2196/27633 · Cited by 1,694
Self-citationEndogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement
Goodarzi, H., Liu, X., Nguyen, H. C. B., Zhang, S., Fish, L., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2015.02.053 · Cited by 949
Lánczky, A., Nagy, Á., Bottai, G., Munkácsy, G., Szabó, A., Santarpia, L., & Győrffy, B. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4013-7 · Cited by 768
Self-citationNetwork-based stratification of tumor mutations
Hofree, M., Shen, J. P., Carter, H., Gross, A., & Ideker, T. (2013) · Nature Methods · doi:10.1038/nmeth.2651 · Cited by 737
Cheon, D.-J., Tong, Y., Sim, M.-S., Dering, J., Berel, D., Cui, X., Lester, J., Beach, J. A., Tighiouart, M., Walts, A. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1256 · Cited by 373
Rodriguez-Garcia, A., Lynn, R. C., Poussin, M., Eiva, M. A., Shaw, L. C., O’Connor, R. S., Minutolo, N. G., Casado-Medrano, V., Lopez, G., Matsuyama, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20893-2 · Cited by 341
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Xiao, Y., Ma, D., Yang, Y.-S., Yang, F., Ding, J.-H., Gong, Y., Jiang, L., Ge, L.-P., Wu, S.-Y., Yu, Q., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00614-0 · Cited by 326
Sublethal cytochrome c release generates drug-tolerant persister cells
Kalkavan, H., Chen, M. J., Crawford, J. C., Quarato, G., Fitzgerald, P., Tait, S. W. G., Goding, C. R., & Green, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.07.025 · Cited by 255
Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness
Avgustinova, A., Iravani, M., Robertson, D., Fearns, A., Gao, Q., Klingbeil, P., Hanby, A. M., Speirs, V., Sahai, E., Calvo, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms10305 · Cited by 180
Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2
Keskin, D., Kim, J., Cooke, V. G., Wu, C.-C., Sugimoto, H., Gu, C., De Palma, M., Kalluri, R., & LeBleu, V. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.035 · Cited by 165
Ferrari, N., Ranftl, R., Chicherova, I., Slaven, N. D., Moeendarbary, E., Farrugia, A. J., Lam, M., Semiannikova, M., Westergaard, M. C. W., Tchou, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07987-0 · Cited by 164
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife · doi:10.7554/elife.47327 · Cited by 145
Self-citationBuchanan, P. C., Boylan, K. L. M., Walcheck, B., Heinze, R., Geller, M. A., Argenta, P. A., & Skubitz, A. P. N. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746859 · Cited by 73
Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer
Li, Y., Guo, H., Jin, C., Qiu, C., Gao, M., Zhang, L., Liu, Z., & Kong, B. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.008 · Cited by 28
Identifying miRNA-mRNA regulation network of major depressive disorder in ovarian cancer patients.
Wu, C., Zhao, Y., Liu, Y., Yang, X., Yan, M., Min, Y., Pan, Z., Qiu, S., Xia, S., Yu, J., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9243 · Cited by 26
Metadata
- Authors
- Győrffy, B., Lánczky, A., & Szállási, Z.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2012-01-25
- Volume
- 19
- Issue
- 2
- Pages
- 197-208
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2143017330
- Cited by
- 970
- References
- 81
- FWCI
- 28.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.